Zhitong Finance App News, Buchang Pharmaceutical (603858.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for the oral solution of atomoxetine hydrochloride approved and issued by the State Drug Administration. This medication is used to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 and over.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.